Announcements Trials
Browse Landscape

Phase

Phase NA 9Phase 2 4Phase 3 3Phase EARLY_PHASE1 2Phase 4 1Phase 1/2 1Phase 1 1

Status

Completed 6Recruiting 3Active not recruiting 2Withdrawn 1Unknown 1Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 1

Interventions

Cyclophosphamide 37Gemcitabine 31Paclitaxel 27Cisplatin 27Carboplatin 27Capecitabine 27camrelizumab 24Nivolumab 23apatinib 22Oxaliplatin 21fludarabine 20Radiotherapy 20toripalimab 17Immunotherapy, Adoptive 17Drug Therapy 17pembrolizumab 16Docetaxel 16Dexamethasone 15Bevacizumab 15N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 14Injections 14tislelizumab 13Temozolomide 13Rituximab 13Cetuximab 13Irinotecan 12130-nm albumin-bound paclitaxel 11anlotinib 10Fluorouracil 10Trastuzumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Unknown × Fluorodeoxyglucose F18 × Clear all
NCT05506566 2023-09-21

68Ga-FAP-CHX PET/CT : Dosimetry and Preliminary Clinical Translational Studies

First Affiliated Hospital of Fujian Medical University

Phase 1/2 Unknown
50 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡